Contents and Formulations of Platelet-Rich Plasma

Operative Techniques in Orthopaedics

Volumn 22, Issue 1, 2012, Pages 33-42

  Wasterlain, Amy S ^a   Braun, Hillary J ^a   Dragoo, Jason L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Composition; Contents; Formulation; Mechanism; Platelet rich plasma

Indexed keywords

CALCIUM CHLORIDE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EPIDERMAL GROWTH FACTOR; FIBRIN; FIBRIN GLUE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; HUMAN GROWTH HORMONE; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ARTICLE; BLOOD COMPONENT THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; FIBROBLAST; FREEZE THAWING; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; LEUKOCYTE FUNCTION; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA;

EID: 84857991334     PISSN: 10486666     EISSN: 15583848     Source Type: Journal    
DOI: 10.1053/j.oto.2011.11.001     Document Type: Article

References (68)

1. Rehfeldt F., Engler A.J., Eckhardt A., et al. Cell responses to the mechanochemical microenvironment-Implications for regenerative medicine and drug delivery. Adv Drug Deliv Rev 2007, 59:1329-1339.
2. Foster T.E., Puskas B.L., Mandelbaum B.R., et al. Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med 2009, 37:2259-2272.
3. Marx R.E. Platelet-rich plasma (PRP): What is PRP and what is not PRP?. Implant Dent 2001, 10:225-228.
4. Creaney L., Hamilton B. Growth factor delivery methods in the management of sports injuries: The state of play. Br J Sports Med 2008, 42:314-320.
5. Anitua E., Sánchez M., Zalduendo M.M., et al. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif 2009, 42:162-170.
6. Sundman E.A., Cole B.J., Fortier L.A. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011, 39:2135-2140.
7. de Jonge S., de Vos R.J., Weir A., et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: A double-blind randomized placebo-controlled trial. Am J Sports Med 2011, 39:1623-1629.
8. Peerbooms J.C., Sluimer J., Bruijn D.J., et al. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010, 38:255-262.
9. Zimmermann R., Jakubietz R., Jakubietz M., et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion 2001, 41:1217-1224.
10. Eppley B.L., Woodell J.E., Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg 2004, 114:1502-1508.
11. Araki J, Jona M, Suga H, et al: Optimized preparation method of platelet-concentrated plasma (PCP) and non-coagulating platelet-derived factor concentrates (PFC): Maximization of platelet concentration and removal of fibrinogen. Tissue eng Part C Methods (in press).
12. Haynesworth SE, Kadiyala S, Liang LN: Mitogenic stimulation of human mesenchymal stem cells by platelet release suggest a mechanism for enhancement of bone repair by platelet concentrates. Presented at the 48th Meeting of the Orthopaedic Research Society, 2002, Boston, MA.
13. Liu Y., Kalén A., Risto O., et al. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen 2002, 10:336-340.
14. Mastrangelo A.N., Vavken P., Fleming B.C., et al. Reduced platelet concentration does not harm PRP effectiveness for ACL repair in a porcine in vivo model. J Orthop Res 2011, 29:1002-1007.
15. Yamaguchi R, Terashima H, Yoneyama S, et al: Effects of platelet-rich plasma on intestinal anastomotic healing in rats: PRP concentration is a key factor. J Surg Res (in press).
16. Freeman M.R., Schneck F.X., Gagnon M.L., et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995, 55:4140-4145.
17. Nielsen H.J., Werther K., Mynster T., et al. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999, 39:1078-1083.
18. McCarrel T., Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 2009, 27:1033-1042.
19. Faurschou M., Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003, 5:1317-1327.
20. Khalafi R.S., Bradford D.W., Wilson M.G. Topical application of autologous blood products during surgical closure following a coronary artery bypass graft. Eur J Cardiothorac Surg 2008, 34:360-364.
21. Everts P.A., Devilee R.J., Brown Mahoney C., et al. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome. A prospective randomized double-blind study. Eur Surg Res 2008, 40:203-210.
22. Mishra A., Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006, 34:1774-1778.
23. Laurens N., Koolwijk P., de Maat M.P. Fibrin structure and wound healing. J Thromb Haemost 2006, 4:932-939.
24. Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009, 27:158-167.
25. Flick M.J., Du X., Degen J.L. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) 2004, 229:1105-1110.
26. de Maat M.P., Verschuur M. Fibrinogen heterogeneity: Inherited and noninherited. Curr Opin Hematol 2005, 12:377-383.
27. Clark R.A. Fibrin and wound healing. Ann N Y Acad Sci 2001, 936:355-367.
28. van Hinsbergh V.W., Collen A., Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001, 936:426-437.
29. Anitua E., Andia I., Ardanza B., et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004, 91:4-15.
30. Min J.K., Lee Y.M., Kim J.H., et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005, 18:300-307.
31. Doessing S., Holm L., Heinemeier K.M., et al. GH and IGF1 levels are positively associated with musculotendinous collagen expression: Experiments in acromegalic and GH deficiency patients. Eur J Endocrinol 2010, 163:853-862.
32. Gustafsson T., Kraus W.E. Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci 2001, 6:D75-D89.
33. Sánchez M., Azofra J., Anitua E., et al. Plasma rich in growth factors to treat an articular cartilage avulsion: A case report. Med Sci Sports Exerc 2003, 35:1648-1652.
34. Banfi G., Corsi M.M., Volpi P. Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications?. Br J Sports Med 2006, 40:816.
35. Ljungqvist A., Schwellnus M.P., Bachl N., et al. International Olympic Committee consensus statement: Molecular basis of connective tissue and muscle injuries in sport. Clin Sports Med 2008, 27:231-239. x-xi.
36. WADA Technical Document TD2010DL v1.0, approved 08 May 2010. Decision Limits for the Confirmatory Quantification of Threshold Substances. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2010DLv1.0_Decision%20Limits%20for%20the%20Confirmatory%20Quantification%20of%20Threshold%20Substances_May%2008%202010_EN.doc.pdf.
37. Kniess A., Ziegler E., Kratzsch J., et al. Potential parameters for the detection of hGH doping. Anal Bioanal Chem 2003, 376:696-700.
38. Anitua E., Andía I., Sanchez M., et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res 2005, 23:281-286.
39. Juul A., Scheike T., Pedersen A.T., et al. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod 1997, 12:2123-2128.
40. de Mos M., van der Windt A.E., Jahr H., et al. Can platelet-rich plasma enhance tendon repair?. A cell culture study. Am J Sports Med 2008, 36:1171-1178.
41. He L., Lin Y., Hu X., et al. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:707-713.
42. Marx R.E., Carlson E.R., Eichstaedt R.M., et al. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85:638-646.
43. Weibrich G., Kleis W.K., Hafner G., et al. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 2002, 30:97-102.
44. Castillo T.N., Pouliot M.A., Kim H.J., et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 2011, 39:266-271.
45. Felisaz N., Boumediene K., Ghayor C., et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 1999, 7:255-264.
46. Roman-Blas J.A., Stokes D.G., Jimenez S.A. Modulation of TGF-beta signaling by proinflammatory cytokines in articular chondrocytes. Osteoarthritis Cartilage 2007, 15:1367-1377.
47. Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999, 14:529-535.
48. Weibrich G., Kleis W.K., Hitzler W.E., et al. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: A technical report. Int J Oral Maxillofac Implants 2005, 20:118-123.
49. Pietrzak W.S., An Y.H., Kang Q.K., et al. Platelet-rich and platelet-poor plasma: Development of an animal model to evaluate hemostatic efficacy. J Craniofac Surg 2007, 18:559-567.
50. Mazzucco L., Balbo V., Cattana E., et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang 2009, 97:110-118.
51. Anitua E., Sanchez M., Nurden A.T., et al. Autologous fibrin matrices: A potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A 2006, 77:285-293.
52. Brass L.F. Thrombin and platelet activation. Chest 2003, 124(suppl 3):18S-25S.
53. Roussy Y., Bertrand Duchesne M.P., Gagnon G. Activation of human platelet-rich plasmas: Effect on growth factors release, cell division and in vivo bone formation. Clin Oral Implants Res 2007, 18:639-648.
54. Harrison S., Vavken P., Kevy S., et al. Platelet activation by collagen provides sustained release of anabolic cytokines. Am J Sports Med 2011, 39:729-734.
55. Anitua E, Alkhraisat MH, Orive G: Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release (in press).
56. Cognasse F., Hamzeh-Cognasse H., Lafarge S., et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: An in vitro study. Transfusion 2009, 49:91-98.
57. Hartley P.S., Savill J., Brown S.B. The death of human platelets during incubation in citrated plasma involves shedding of CD42b and aggregation of dead platelets. Thromb Haemost 2006, 95:100-106.
58. Landi E.P., Roveri E.G., Ozelo M.C., et al. Effects of high platelet concentration in collecting and freezing dry platelets concentrates. Transfus Apher Sci 2004, 30:205-212.
59. Johnson L.N., Winter K.M., Reid S., et al. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. Cryobiology 2011, 62:100-106.
60. Farndale R.W., Siljander P.R., Onley D.J., et al. Collagen-platelet interactions: Recognition and signalling. Biochem Soc Symp 2003, 70:81-94.
61. Fufa D., Shealy B., Jacobson M., et al. Activation of platelet-rich plasma using soluble type I collagen. J Oral Maxillofac Surg 2008, 66:684-690.
62. Leitner G.C., Gruber R., Neumüller J., et al. Platelet content and growth factor release in platelet-rich plasma: A comparison of four different systems. Vox Sang 2006, 91:135-139.
63. Woodell-May J.E., Ridderman D.N., Swift M.J., et al. Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. J Craniofac Surg 2005, 16:749-756. discussion 57-59.
64. Kevy S.V., Jacobson M.S. Comparison of methods for point of care preparation of autologous platelet gel. J Extra Corpor Technol 2004, 36:28-35.
65. Coetzee J.C., Pomeroy G.C., Watts J.D., et al. The use of autologous concentrated growth factors to promote syndesmosis fusion in the agility total ankle replacement. A preliminary study. Foot Ankle Int 2005, 26:840-846.
66. Marx R.E. Platelet-rich plasma: Evidence to support its use. J Oral Maxillofac Surg 2004, 62:489-496.
67. Zhang J., Wang J.H. Platelet-rich plasma releasate promotes differentiation of tendon stem cells into active tenocytes. Am J Sports Med 2010, 38:2477-2486.
68. Fallouh L., Nakagawa K., Sasho T., et al. Effects of autologous platelet-rich plasma on cell viability and collagen synthesis in injured human anterior cruciate ligament. J Bone Joint Surg Am 2010, 92:2909-2916.